Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

RSK inhibitors as potential anticancer agents: Discovery, optimization, and challenges
Ying Sun, Lichao Tang, Chengyong Wu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 251, pp. 115229-115229
Closed Access | Times Cited: 12

Showing 12 citing articles:

Systematic and comprehensive insights into HIF-1 stabilization under normoxic conditions: implications for cellular adaptation and therapeutic strategies in cancer
Jiayi Zhang, Mengqin Yao, Siyu Xia, et al.
Cellular & Molecular Biology Letters (2025) Vol. 30, Iss. 1
Open Access | Times Cited: 3
Interfacial Asymmetrically Coordinated Zn−MOF for High‐Efficiency Electrosynthetic Oxime
Jiawei Kang, Peisen Liao, Runan Xiang, et al.
Angewandte Chemie International Edition (2025)
Closed Access
Interfacial Asymmetrically Coordinated Zn−MOF for High‐Efficiency Electrosynthetic Oxime
Jiawei Kang, Peisen Liao, Runan Xiang, et al.
Angewandte Chemie (2025)
Closed Access
Discovery of 2,4-dianilinopyrimidine derivatives as novel p90 ribosomal S6 protein kinase (RSK) inhibitors
Chun Han, Guo Chaohua, Xumei Zheng, et al.
European Journal of Medicinal Chemistry (2025), pp. 117590-117590
Closed Access
The choreography of protein kinase PDK1 and its diverse substrate dance partners
Alejandro E. Leroux, Ricardo M. Biondi
Biochemical Journal (2023) Vol. 480, Iss. 19, pp. 1503-1532
Closed Access | Times Cited: 10
RSK1 and RSK2 as therapeutic targets: an up-to-date snapshot of emerging data
Ashley N. Spirrison, Deborah A. Lannigan
Expert Opinion on Therapeutic Targets (2024), pp. 1-13
Open Access | Times Cited: 3
Discovery of potential RSK1 inhibitors for cancer therapy using virtual screening, molecular docking, molecular dynamics simulation, and MM/GBSA calculations
Sevil Kalın, Ferah Cömert Önder
Journal of Biomolecular Structure and Dynamics (2023), pp. 1-21
Open Access | Times Cited: 7
Targeting the p90RSK/MDM2/p53 Pathway Is Effective in Blocking Tumors with Oncogenic Up-Regulation of the MAPK Pathway Such as Melanoma and Lung Cancer
Immacolata Maietta, Eleonora Viscusi, Stefano Laudati, et al.
Cells (2024) Vol. 13, Iss. 18, pp. 1546-1546
Open Access | Times Cited: 2
RSK3 switches cell fate: from stress-induced senescence to malignant progression
Anda Huna, Jean‐Michel Flaman, Catalina Lodillinsky, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 5
Regulation and function of the RSK family in colorectal cancer
Ziyi Wang, Xiangming Han, Zhe Lei, et al.
Journal of Cancer Metastasis and Treatment (2024)
Open Access | Times Cited: 1
Mitochondrial Signatures Shape Phenotype Switching and Apoptosis in Response to PLK1 and RSK Inhibitors in Melanoma
Émilie Lavallée, Maëline Roulet-Matton, Viviane Giang, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Mitochondrial signatures shape phenotype switching and apoptosis in response to PLK1 inhibitors
Émilie Lavallée, Maëline Roulet-Matton, Viviane Giang, et al.
Life Science Alliance (2024) Vol. 8, Iss. 3, pp. e202402912-e202402912
Open Access
Page 1

Scroll to top